Rayego-MateosSMorgado-PascualJLValdivielsoJMSanzABBosch-PanaderoERodrigues-DezRRet al
Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite
doi: 10.1074/jbc.RA118.001921 16 WeiXSongHYinLRizzoMGSidhuRCoveyDFet al
This makes it challenging to estimate out-of-pocket costs without considering various mitigating factors
You can offer them the guidance, support, and tools they need to get affordable access to life-changing medications
The tirzepatide injection uses J3490 plus 96372